Premium
Auraptene regulates gene expression involved in lipid metabolism through PPARα activation in diabetic obese mice
Author(s) -
Takahashi Nobuyuki,
Senda Mari,
Lin Shan,
Goto Tsuyoshi,
Yano Masamichi,
Sasaki Takao,
Murakami Shigeru,
Kawada Teruo
Publication year - 2011
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201100401
Subject(s) - peroxisome proliferator activated receptor , endocrinology , medicine , lipid metabolism , hyperlipidemia , triglyceride , adipocyte , peroxisome , skeletal muscle , receptor , agonist , biology , beta oxidation , carbohydrate metabolism , chemistry , diabetes mellitus , metabolism , cholesterol , adipose tissue
Scope: Peroxisome proliferator‐activated receptor‐α (PPARα) is a key regulator of circulating lipid level. Thus, various food‐derived compounds that activate PPARα as agonists have been screened and characterized. Methods and results: We investigated the effects of auraptene, a citrus‐derived compound serving as a PPARα agonist in vitro, on abnormalities in lipid and glucose metabolisms. In high‐fat‐diet (HFD)‐fed KK‐Ay diabetic obese mice, auraptene treatment suppressed hyperlipidemia and triglyceride accumulation in the liver and skeletal muscle, and increased the mRNA expression levels of the PPARα target genes involved in fatty acid oxidation in the liver and skeletal muscle. Moreover, the adipocyte size in the auraptene‐treated mice was significantly smaller than that in the control HFD‐fed mice resulting in the improvement of HFD‐induced hyperglycemia and abnormalities in glucose tolerance. Conclusions: These findings indicate that auraptene activates PPARα also in vivo and its treatment may improve abnormalities in lipid and glucose metabolisms, suggesting that auraptene is a valuable food‐derived compound for managing metabolic disorders.